Table 1. Baseline Characteristics.

	ST (n = 143)	HM (n = 62)	Total (n = 205)
Sex, n (%)
Male	92 (64)	34 (54.8)	128 (62.4)
Age, years
Range	35–93	38–89	35–93
Median (IQR)	73 (70 to 80)	73 (69 to 75)	73 (69–79)
Race, n (%)
White	134 (94)	57 (91.9)	191 (93.7)
American Indian	5 (3.5)	0 (0)	5 (2.4)
Asian	1 (0.69)	0 (0)	1 (0.5)
Black	2 (1.39)	4 (6.45)	6 (2.9)
Two or more races	0 (0)	1 (1.61)	1 (0.5)
Smoking status, n (%)
Current	4 (2.8)	1 (1.61)	5 (2.4)
Former	49 (34)	4 (6.45)	53 (25.8)
Never	90 (63)	57 (92)	147 (73.7)
Other chronic conditions
Patients with any condition, n (%)	124 (60.4)	47 (75.8)	171 (83.4)
Mean number chronic conditions ± STD	2.0 ± 1.4	1.3 ± 1.1	1.8 ± 1.3
Patients with hypertension, n (%)	105 (73.4)	37 (59.6)	142 (69.3)
Patients with diabetes, n (%)	50 (35)	11 (17.7)	61 (29.8)
Patients with CAD, n (%)	42 (29.3)	6 (9.6)	48 (23.4)
Other chronic conditions, n (%)	90 (63)	23 (37)	113 (55.1)
Primary health insurance provider, n (%)
Medicare	141 (98.6)	60 (96.7)	201 (98)
Commercial	2 (1.3)	1 (1.6)	2 (0.97)
Uninsured	2 (1.3)	1 (1.6)	2 (0.97)
Cancer type
Solid tumor, n (%)
Prostate	39 (27.3)	–	–
GI	28 (19.6)	–	–
Lung	17 (11.9)	–	–
Breast	17 (11.9)	–	–
Pancreatic	13 (4.9)	–	–
Renal	7 (4.9)	–	–
Other solid tumor	22 (15.4)	–	–
Hematologic, n (%)
Acute leukemia	–	19 (30.6)	–
Multiple myeloma	–	18 (29)	–
Lymphoma	–	17 (27.4)	–
Chronic leukemia	–	6 (9.6)	–
Other	–	7 (11.2)	–
Oncologic treatment goals/history
Goals of cancer care, n (%)
Curative/Life-prolonging	77 (53.8)	45 (72.5)	122 (59.5)
Palliative	55 (38.4)	14 (22.5)	69 (33.7)
New diagnosis	10 (7)	2 (3.2)	12 (5.9)
Cancer treatment line, n (%)
New diagnosis	12 (7)	4 (6.45)	16 (7.8)
1st line	50 (35)	12 (19.3)	62 (30.2)
2nd–4th	62 (43.4)	37 (59.6)	99 (48.3)
5th and beyond	21 (14.7)	7 (11.2)	28 (13.7)
Stage of solid tumor cancer
Stage I–III	26 (18.1)	–	–
Stage IV	106 (74.1)	–	–
Not stated/not yet staged	11 (7.7)	–	–

Note. ST = solid tumor; HM = hematologic malignancy.